2020 Wuhan API site obtains WC documents for multiple products （Liraglutide, Ganirelix acetate, Terlipressin acetate, Eptifibatide, Atosiban acetate, Oxytocin, Octreotide acetate, Carbetocin, Desmopressin acetate）

2019 Obtained market license from Indonesian authority for Terlipressin inj.

2018 Indonesia GMP inspection

2018 EU EMA inspection

2018 South Korea MFDS GMP inspection

2018 US FDA GMP inspection

2017 Brazilian ANVISA inspection on FDF line

2016 Launched Carbetocin project

2015 US FDA GMP inspection

2015 EU AEMPS GMP inspection

2015 Non-invasive CGM device

2010 Pakistan GMP inspection (FDF)

2010 Elected as one of “The Chinese Top 200 Potential Enterprises in 2010”by Forbes.

2013 Received GMP approval from CFDA for the new FDF facility--Pingshan site.

2011 2011 Hybio goes public. The shares are listed on the Shenzhen Stock Exchange (stock code: 300199)

2014 Acquired GS Changee Bio-Pharma Ltd.

2014 Eptifibatide injection ANDA got approved by US authority

1998 Hybio was Founded

2004 Launched Thymopentin, Somatostatin (Inj.) projects

2006 Eptifibatide injection, submitted as the 1st NDA of Hybio in Chinese domestic market

2005 Nashan headquarters, received its 1st GMP approval for the site

2000 Became the 1st Peptide R&D Center in China

2009 Launched Terlipressin Injection as the 1st generic in China